Alexion Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company. The company develops novel therapeutics based on the biological breakthrough known as ribonucleic acid interference. The company applies ribonucleic acid interference to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies. This discovery enables the creation of a broad new class of human therapeutics. Alnylam Pharmaceuticals maintains partnerships with leading pharmaceutical and medical technology companies to drive further developments and capabilities. Major alliances include Merck, Medtronic and Novartis. Alnylam Pharmaceuticals, founded in 2002, maintains global headquarters in Cambridge, Mass., and has an additional operating unit in Kulmbach, Germany.

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website

Ocular Therapeutix, located in Bedford, MA, is focused on transforming the treatment of retinal diseases, which significantly impact millions of Americans and often lead to blindness. Their ongoing clinical innovations, including the investigational therapy AXPAXLI (OTX-TKI), aim to reduce the treatment burden associated with retinal conditions like wet Age-Related Macular Degeneration. With a team that boasts extensive expertise and a strong track record in retinal disease management, Ocular Therapeutix aspires to improve long-term outcomes for patients by minimizing the need for frequent treatments. Their pipeline reflects a commitment to redefining patient care through advanced therapies and clinical trials. Generated from the website